Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company’s diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s Financial Overview

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) declined -6.7% yesterday to close its trading session at $34.26. The company has 1 year Price Target of $71.63. Sarepta Therapeutics, Inc. has 52-Week high of $63.73 and 52-Week Low of $8. The stock touched its 52-Week High on Sep 28, 2016 and 52-Week Low on Apr 26, 2016. The stock traded with the volume of 2.79 Million shares yesterday. The firm shows the market capitalization of $1.87 Billion.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $-1.18/share against the analyst consensus estimate of $-1.32/share. The difference between the actual and expected EPS is $0.14 a share with a surprise factor of 10.6%.

The firm is trading with SMA20 of -10.8 Percent, SMA50 of -28.05 Percent and SMA200 of 25.57 percent. Sarepta Therapeutics, Inc. has P/S value of 1438.66 while its P/B value stands at 4.04. Similarly, the company has Return on Assets of -82.6 percent, Return on Equity of -113.3 percent and Return on Investment of -103 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.

Many brokerage firms are involved in issuing their ratings on Sarepta Therapeutics, Inc. (NASDAQ:SRPT). On 27-Oct-16 Morgan Stanley Initiated Sarepta Therapeutics, Inc. Stock  to Equal-Weight. Another firm also rated the stock on 18-Oct-16 where Credit Suisse Initiated the stock to Outperform.

The Stock currently has Analyst’ mean Recommendation of 1.9 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 16 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 68.00, with a high estimate of 106.00 and a low estimate of 46.00. The median estimate represents a +98.48% increase from the last price of 34.26.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Zayo Group Holdings, Inc. (NYSE:ZAYO)

Zayo Group Holdings, Inc. is a provider of bandwidth infrastructure services, including dark fiber, wavelengths, SONET, Ethernet, IP services, and carrier-neutral colocation and interconnection. Its customers include wireline and wireless carriers, and high-bandwidth enterprises from disaster recovery, media content, educational, financial, government, healthcare, and other industries. Zayo Group Holdings, Inc. is headquartered in Boulder, Colorado.

Zayo Group Holdings, Inc. (NYSE:ZAYO)’s Financial Outlook

The 13 analysts offering 12-month price forecasts for Zayo Group Holdings Inc have a median target of 36.00, with a high estimate of 41.00 and a low estimate of 20.00. The median estimate represents a +4.35% increase from the last price of 34.50.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Zayo Group Holdings, Inc. has a Consensus Recommendation of 1.85. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock fell -0.61% and closed its last trading session at $34.5. The company has the market capitalization of $8.39 Billion. The stock has 52-week high of $35.65 and 52-Week low of $19.59. The firm touched its 52-Week high on Nov 21, 2016 and 52-Week low on Feb 12, 2016. The company has volume of 13.52 Million shares. The company has a total of 243.12 Million shares outstanding.

Zayo Group Holdings, Inc. (NYSE:ZAYO) in the last quarter reported its actual EPS of $0.06/share where the analyst estimated EPS was $0.05/share. The difference between the actual and Estimated EPS is $0.01. This shows a surprise factor of 20 percent.

The company has YTD performance of 29.75 percent. Beta for Zayo Group Holdings, Inc. stands at 0 while its ATR (average true range) is 0.8. The company has Weekly Volatility of 2.17%% and Monthly Volatility of 2.42%%.

Zayo Group Holdings, Inc. has distance from 20-day Simple Moving Average (SMA20) of 2.95%, Distance from 50-Day Simple Moving Average of 8.15 percent and Distance from 200-Day Simple Moving Average of 22.59%.

The Company currently has ROA (Return on Assets) of -0.7 percent, Return on Equity (ROE) of -3.7 Percent and Return on Investment (ROI) of 3.7% with Gross margin of 65.6 percent and Operating & Profit margin of 13% and -2.4% respectively.